查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2015466

弓蟲症檢測市場：市場洞察、競爭格局及市場預測（2033 年）

Toxoplasmosis Testing Market Insights, Competitive Landscape, and Market Forecast - 2033
出版日期: | 出版商: Fairfield Market Research | 英文 188 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

隨著全球醫療衛生系統日益重視早期診斷和感染疾病控制，全球 弓蟲症檢測市場正經歷顯著成長。弓蟲症是由弓形蟲（Toxoplasma gondii）寄生蟲引起的感染疾病，仍然是一個重要的公共衛生問題，尤其對孕婦和免疫力人群構成威脅。對快速準確檢測日益成長的需求推動先進診斷解決方案的普及。預計到2026年，該市場規模將達24億美元，2033年將成長至35億美元，預測期內年複合成長率（CAGR）為5.50%。

市場洞察

隨著包括血清學檢測、分子診斷和影像技術在內的多種診斷技術的出現，弓蟲症檢測市場不斷發展。血清學檢測因其價格低廉和易於獲取而仍佔據主導地位，但聚合酵素鏈鎖反應（PCR）等分子診斷技術因其準確性和可靠性而日益受到青睞。

通用感染疾病負擔日益加重以及常規篩檢計畫（尤其是在產前保健領域）的擴展，推動市場成長。此外，檢查室自動化和數位化診斷平台的進步提高了檢測效率，縮短了結果報告時間，並增強了診斷的有效性和擴充性。

市場促進因素

市場成長的主要促進因素之一是全球弓蟲症感染率的上升。這種感染疾病可透過受污染的食物和水傳播，也可透過接觸受感染的動物傳播，對已開發國家和開發中國家都構成廣泛的風險。

另一個主要成長要素是人們對早期檢測重要性的認知不斷提高。早期診斷對於預防嚴重併發症非常重要，尤其是可能造成長期健康後果的性行為感染。

診斷工具的技術進步進一步加速市場擴張。高靈敏度和高特異性檢測方法的開發，以及檢查室自動化程度的提高，提升診斷的準確性和可近性。

此外，老年人和免疫力缺乏人群數量的增加也推動了對可靠檢測解決方案的需求。這些弱勢群體需要定期監測，這進一步促進了市場成長。

商業機會

弓蟲症檢測市場為參與企業提供了巨大的成長機會。由於醫療基礎設施的改善和醫療服務投資的增加，亞太地區和拉丁美洲等新興經濟體預計將成為主要的成長區域。

市場對能夠快速提供準確結果的即時檢測解決方案的需求日益成長。這些技術在偏遠或資源匱乏的環境中特別有用，因為在這些地區，獲得中心檢查室檢測服務可能受到限制。

此外，將人工智慧和資料分析等先進技術整合到診斷平台中，為創新開闢了新的途徑。這些工具能夠提高診斷準確性，提高工作流程效率，並為臨床決策提供支援。

策略聯盟、新產品發布和收購也為市場參與企業創造了鞏固市場地位和拓展產品線的機會。持續加大研發投入可望推動市場創新與競爭力提升。

區域分析

北美在弓蟲症檢測市場繼續保持主導地位，這得益於其先進的醫療保健體系、高度的公眾意識以及對創新診斷技術的積極應用。主要行業參與者的存在進一步鞏固了該地區的市場主導地位。

歐洲佔了較大的市場佔有率，這主要得益於政府主導的各項措施不斷增加，以及對孕產婦和新生兒健康的高度重視。該地區完善的醫療衛生基礎設施也為診斷檢測的廣泛普及提供了保障。

預計亞太地區在預測期內將經歷最快的成長。快速的都市化、不斷上漲的醫療保健成本以及人們對感染疾病認知的提高是該地區市場擴張的主要促進因素。

拉丁美洲、中東和非洲也經歷了溫和成長，這得益於醫療保健服務的持續改善以及對疾病預防和早期診斷的日益重視。

主要企業

全球弓蟲症檢測市場的特點是多家主要企業進入該市場，這些企業著重創新和策略擴張。主要企業包括：

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • Affymetrix Inc.
  • Beckman Coulter Inc.
  • Biotest
  • Cepheid Inc.
  • GenBio
  • Danaher Corporation
  • Thermo Fisher Scientific
  • Biomerica Inc.
  • Biomerix

這些組織正積極致力於開發先進的診斷解決方案，並透過夥伴關係和產品創新在全球企業發展。

區隔

依測試類型：

  • 血清學檢測
  • 染色方法
  • 間接血凝反應
  • 直接團聚法
  • ELISA
  • PCR
  • 超音波檢查
  • MRI
  • 切片檢查

檢體：

  • 血液檢體
  • 羊水
  • 腦脊髓液

依最終用戶分類：

  • 醫院
  • 診所
  • 診斷檢查室

依地區：

  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 亞太地區
  • 中東和非洲

目錄

第1章 執行摘要

第2章 市場概覽

  • 市場定義與細分
  • 市場動態
    • 促進因素
    • 抑制因子
    • 市場機會
  • 價值鏈分析
  • 新冠疫情影響分析
  • 波特五力分析
  • 俄烏衝突的影響
  • PESTLE分析
  • 監管分析
  • 價格趨勢分析
    • 當前價格及未來預測（2025-2033）
    • 價格影響因素

第3章 2020-2033年全球弓漿蟲病檢測市場展望

  • 全球弓漿蟲病檢測市場展望，依檢測類型和價值（十億美元），2020-2033年
    • 血清學檢測
    • 染料測試
    • 間接血凝試驗
    • 直接凝集反應試驗
    • ELISA
    • PCR
    • 超音波
    • MRI
    • 切片檢查
  • 全球弓漿蟲病檢測市場展望，依檢體類型和價值（十億美元），2020-2033年
    • 血液樣本
    • 羊水
    • 腦脊髓液
  • 全球弓漿蟲病檢測市場展望，依最終用戶分類，價值（十億美元），2020-2033年
    • 醫院
    • 診所
    • 診斷檢查室
  • 全球弓漿蟲病檢測市場展望（依地區分類，價值十億美元），2020-2033年
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第4章 2020-2033年北美弓漿蟲病檢測市場展望

第5章 2020-2033年歐洲弓漿蟲病檢測市場展望

第6章 2020-2033年亞太地區弓漿蟲病檢測市場展望

第7章 2020-2033年拉丁美洲弓漿蟲病檢測市場展望

第8章 2020-2033年中東和非洲弓蟲症檢測市場展望

第9章 競爭情勢

  • 公司與細分市場熱圖
  • 2025年各公司市場佔有率分析
  • 競爭儀錶板
  • 公司簡介
    • Abbott Laboratories
    • Bio-Rad Laboratories Inc.
    • Affymetrix Inc.
    • Beckman Coulter Inc.
    • Biotest
    • Cepheid Inc.
    • GenBio
    • Danaher Corporation
    • Thermo Fisher Scientific

第10章 附錄

簡介目錄

The global toxoplasmosis testing market is gaining notable momentum as healthcare systems worldwide intensify their focus on early diagnosis and infectious disease management. Toxoplasmosis, an infection caused by the parasite Toxoplasma gondii, remains a significant public health concern, particularly among pregnant women and individuals with weakened immune systems. The need for timely and accurate detection is driving the adoption of advanced diagnostic solutions. The market is projected to reach USD 2.4 billion in 2026 and is anticipated to grow to USD 3.5 billion by 2033, reflecting a compound annual growth rate (CAGR) of 5.50% during the forecast period.

Market Insights

The toxoplasmosis testing market is evolving with a wide array of diagnostic technologies, including serological assays, molecular diagnostics, and imaging techniques. Serological testing continues to dominate due to its affordability and accessibility, while molecular methods such as polymerase chain reaction (PCR) are increasingly preferred for their precision and reliability.

The growing burden of zoonotic diseases and the expansion of routine screening programs, particularly in prenatal care, are contributing to market growth. Additionally, advancements in laboratory automation and digital diagnostic platforms are enhancing testing efficiency and reducing turnaround times, making diagnostics more effective and scalable.

Market Drivers

A key factor driving market growth is the rising global incidence of toxoplasmosis infections. The infection can spread through contaminated food, water, and exposure to infected animals, making it a widespread risk across both developed and developing regions.

Increasing awareness regarding the importance of early detection is another major growth driver. Early diagnosis is essential in preventing severe complications, especially congenital infections that can have long-term health implications.

Technological progress in diagnostic tools is further accelerating market expansion. The development of highly sensitive and specific testing methods, along with automation in laboratories, is improving diagnostic accuracy and accessibility.

In addition, the growing population of elderly individuals and immunocompromised patients is increasing the demand for reliable testing solutions. These vulnerable groups require regular monitoring, further supporting the growth of the market.

Business Opportunity

The toxoplasmosis testing market offers substantial opportunities for industry participants. Emerging economies in Asia Pacific and Latin America are expected to be key growth areas due to improving healthcare infrastructure and rising investments in healthcare services.

There is a growing demand for point-of-care testing solutions that deliver rapid and accurate results. These technologies are particularly valuable in remote and resource-limited settings, where access to centralized laboratories may be limited.

Moreover, the integration of advanced technologies such as artificial intelligence and data analytics into diagnostic platforms is opening new avenues for innovation. These tools can enhance diagnostic accuracy, streamline workflows, and support clinical decision-making.

Strategic collaborations, product launches, and acquisitions are also creating opportunities for market players to strengthen their presence and expand their product offerings. Continuous investment in research and development is expected to drive innovation and competitiveness in the market.

Region Analysis

North America continues to hold a leading position in the toxoplasmosis testing market, supported by advanced healthcare systems, high awareness levels, and strong adoption of innovative diagnostic technologies. The presence of major industry players further reinforces the region's dominance.

Europe represents a significant share of the market, driven by increasing government initiatives and a strong emphasis on maternal and neonatal health. The region's well-established healthcare infrastructure supports widespread adoption of diagnostic testing.

Asia Pacific is projected to witness the fastest growth over the forecast period. Rapid urbanization, rising healthcare expenditure, and increasing awareness about infectious diseases are key factors contributing to market expansion in the region.

Latin America and the Middle East & Africa are also experiencing gradual growth, supported by ongoing improvements in healthcare access and increasing focus on disease prevention and early diagnosis.

Key Players

The global toxoplasmosis testing market is characterized by the presence of several prominent players focused on innovation and strategic expansion. Key companies include:

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • Affymetrix Inc.
  • Beckman Coulter Inc.
  • Biotest
  • Cepheid Inc.
  • GenBio
  • Danaher Corporation
  • Thermo Fisher Scientific
  • Biomerica Inc.
  • Biomerix

These organizations are actively engaged in developing advanced diagnostic solutions and expanding their global footprint through partnerships and product innovations.

Segmentation

By Test Type:

  • Serological Test
  • Dye Test
  • Indirect Hemagglutination Assay
  • Direct agglutination Assay
  • ELISA
  • PCR
  • Ultrasound
  • MRI
  • Biopsy

By Sample:

  • Blood Sample
  • Amniotic Fluid
  • Cerebrospinal Fluid

By End User:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Toxoplasmosis Testing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Toxoplasmosis Testing Market Outlook, 2020-2033

  • 3.1. Global Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Serological Test
    • 3.1.2. Dye Test
    • 3.1.3. Indirect Hemagglutination Assay
    • 3.1.4. Direct agglutination Assay
    • 3.1.5. ELISA
    • 3.1.6. PCR
    • 3.1.7. Ultrasound
    • 3.1.8. MRI
    • 3.1.9. Biopsy
  • 3.2. Global Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 3.2.1. Blood Sample
    • 3.2.2. ABniotic Fluid
    • 3.2.3. Cerebrospinal Fluid
  • 3.3. Global Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.3.1. Hospitals
    • 3.3.2. Clinics
    • 3.3.3. Diagnostic Laboratories
  • 3.4. Global Toxoplasmosis Testing Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Toxoplasmosis Testing Market Outlook, 2020-2033

  • 4.1. North America Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Serological Test
    • 4.1.2. Dye Test
    • 4.1.3. Indirect Hemagglutination Assay
    • 4.1.4. Direct agglutination Assay
    • 4.1.5. ELISA
    • 4.1.6. PCR
    • 4.1.7. Ultrasound
    • 4.1.8. MRI
    • 4.1.9. Biopsy
  • 4.2. North America Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 4.2.1. Blood Sample
    • 4.2.2. ABniotic Fluid
    • 4.2.3. Cerebrospinal Fluid
  • 4.3. North America Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.3.1. Hospitals
    • 4.3.2. Clinics
    • 4.3.3. Diagnostic Laboratories
  • 4.4. North America Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.2. U.S. Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 4.4.3. U.S. Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 4.4.4. Canada Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.5. Canada Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 4.4.6. Canada Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Toxoplasmosis Testing Market Outlook, 2020-2033

  • 5.1. Europe Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Serological Test
    • 5.1.2. Dye Test
    • 5.1.3. Indirect Hemagglutination Assay
    • 5.1.4. Direct agglutination Assay
    • 5.1.5. ELISA
    • 5.1.6. PCR
    • 5.1.7. Ultrasound
    • 5.1.8. MRI
    • 5.1.9. Biopsy
  • 5.2. Europe Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 5.2.1. Blood Sample
    • 5.2.2. ABniotic Fluid
    • 5.2.3. Cerebrospinal Fluid
  • 5.3. Europe Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.3.1. Hospitals
    • 5.3.2. Clinics
    • 5.3.3. Diagnostic Laboratories
  • 5.4. Europe Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.2. Germany Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.3. Germany Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.4. Italy Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.5. Italy Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.6. Italy Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.7. France Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.8. France Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.9. France Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.10. U.K. Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.11. U.K. Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.12. U.K. Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.13. Spain Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.14. Spain Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.15. Spain Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.16. Russia Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.17. Russia Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.18. Russia Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.19. Rest of Europe Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.20. Rest of Europe Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.21. Rest of Europe Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Toxoplasmosis Testing Market Outlook, 2020-2033

  • 6.1. Asia Pacific Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Serological Test
    • 6.1.2. Dye Test
    • 6.1.3. Indirect Hemagglutination Assay
    • 6.1.4. Direct agglutination Assay
    • 6.1.5. ELISA
    • 6.1.6. PCR
    • 6.1.7. Ultrasound
    • 6.1.8. MRI
    • 6.1.9. Biopsy
  • 6.2. Asia Pacific Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 6.2.1. Blood Sample
    • 6.2.2. ABniotic Fluid
    • 6.2.3. Cerebrospinal Fluid
  • 6.3. Asia Pacific Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.3.1. Hospitals
    • 6.3.2. Clinics
    • 6.3.3. Diagnostic Laboratories
  • 6.4. Asia Pacific Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.2. China Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.3. China Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.4. Japan Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.5. Japan Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.6. Japan Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.7. South Korea Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.8. South Korea Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.9. South Korea Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.10. India Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.11. India Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.12. India Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.13. Southeast Asia Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.14. Southeast Asia Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.15. Southeast Asia Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.16. Rest of SAO Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.17. Rest of SAO Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.18. Rest of SAO Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Toxoplasmosis Testing Market Outlook, 2020-2033

  • 7.1. Latin America Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Serological Test
    • 7.1.2. Dye Test
    • 7.1.3. Indirect Hemagglutination Assay
    • 7.1.4. Direct agglutination Assay
    • 7.1.5. ELISA
    • 7.1.6. PCR
    • 7.1.7. Ultrasound
    • 7.1.8. MRI
    • 7.1.9. Biopsy
  • 7.2. Latin America Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 7.2.1. Blood Sample
    • 7.2.2. ABniotic Fluid
    • 7.2.3. Cerebrospinal Fluid
  • 7.3. Latin America Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Diagnostic Laboratories
  • 7.4. Latin America Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.2. Brazil Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.3. Brazil Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 7.4.4. Mexico Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.5. Mexico Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.6. Mexico Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 7.4.7. Argentina Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.8. Argentina Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.9. Argentina Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 7.4.10. Rest of LATAM Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.11. Rest of LATAM Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.12. Rest of LATAM Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Toxoplasmosis Testing Market Outlook, 2020-2033

  • 8.1. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Serological Test
    • 8.1.2. Dye Test
    • 8.1.3. Indirect Hemagglutination Assay
    • 8.1.4. Direct agglutination Assay
    • 8.1.5. ELISA
    • 8.1.6. PCR
    • 8.1.7. Ultrasound
    • 8.1.8. MRI
    • 8.1.9. Biopsy
  • 8.2. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 8.2.1. Blood Sample
    • 8.2.2. ABniotic Fluid
    • 8.2.3. Cerebrospinal Fluid
  • 8.3. Middle East & Africa Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Diagnostic Laboratories
  • 8.4. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.2. GCC Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.3. GCC Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.4. South Africa Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.5. South Africa Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.6. South Africa Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.7. Egypt Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.8. Egypt Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.9. Egypt Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.10. Nigeria Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.11. Nigeria Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.12. Nigeria Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.13. Rest of Middle East Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.14. Rest of Middle East Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.15. Rest of Middle East Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Abbott Laboratories
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Bio-Rad Laboratories Inc.
    • 9.4.3. Affymetrix Inc.
    • 9.4.4. Beckman Coulter Inc.
    • 9.4.5. Biotest
    • 9.4.6. Cepheid Inc.
    • 9.4.7. GenBio
    • 9.4.8. Danaher Corporation
    • 9.4.9. Thermo Fisher Scientific

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations